Mezzion Pharma Co Ltd
KOSDAQ:140410
Mezzion Pharma Co Ltd
Mezzion Pharma Co., Ltd. engages in the development, production, and licensing of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2012-01-20. The firm focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The firm has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
Mezzion Pharma Co., Ltd. engages in the development, production, and licensing of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2012-01-20. The firm focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The firm has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
